Kailera Therapeutics shares surged 62.5% in their Nasdaq debut after raising $625 million in a U.S. IPO priced at the top end of its range....

Wegovy and Ozempic ⁠price cuts will be effective January 1 next year, coinciding with the implementation of new, lower prices for the same ...

LLY stock today: Eli Lilly's stock saw a significant jump following impressive fourth-quarter results and a strong 2026 financial forecast....

Eli Lilly and Novo Nordisk are in a race to dominate India's booming obesity drug market. They are using aggressive marketing, doctor outre...

Novo Nordisk's popular weight-loss drug Wegovy is now available as a pill in the US. The US Food and Drug Administration has approved the o...

Healthify, a prominent player in the Indian health-tech sector, is stepping up its collaborations with firms specializing in weight-loss me...

Obesity, weight-loss medicines: Novo has been scrambling to keep pace in the obesity drug race it started, losing ground to rival Eli Lilly...

Pfizer has agreed to acquire obesity drug developer Metsera for up to $86.25 a share, surpassing Novo Nordisk's final offer. This move mark...

Metsera has accepted Pfizer's $10 billion acquisition offer. This ends a bidding war with rival Novo Nordisk. Pfizer will pay $86.25 per sh...

Pfizer is increasing its offer for Metsera. This comes after a judge rejected Pfizer's attempt to stop rival Novo Nordisk's bid. Pfizer's d...

A fierce bidding war is underway for Metsera, an obesity drug developer. Novo Nordisk has made a $10 billion offer, which Metsera considers...

Novo Holdings is boosting its investments in India. The company is looking at single-specialty hospitals and contract drugmakers. This move...

Pfizer sued Metsera and Novo Nordisk, alleging Metsera breached its merger agreement by deeming Novo's $8.5 billion bid superior. Pfizer se...

Akero Therapeutics stock surged nearly 20% today. Novo Nordisk announced it will acquire Akero for $4.7 billion in cash. The deal values Ak...

Stock Market boom for both companies' shares came as Pfizer said on Monday it would acquire drug developer Metsera in a deal valued at up t...

Novo will pay Hong Kong-based United Laboratories $200 million upfront for the drug, which combines three different mechanisms in an effort...

Novo Nordisk A/S bought Cardior Pharmaceuticals for $1 billion to enhance cardiovascular treatments. Cardior's microRNA-targeting therapies...